Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
BIO Asia–Taiwan 2026Investment SummitMALT1 inhibitor ocipumaltib (CTX-177)CLK inhibitor rogocekib (CTX-712)CDK12 inhibitor CTX-439GCN2 inhibitor
Applicable field (uses covered by this announcement)
Oncology research and development, pharmaceuticals and biotechnology, and business partnering
Launch date15 July 2026 (scheduled speaking date; the event will be held from 15 to 19 July 2026)
Location (as indicated in this announcement)
Fujisawa, Kanagawa Prefecture (head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | BIO Asia–Taiwan 2026, Investment Summit, MALT1 inhibitor ocipumaltib (CTX-177), CLK inhibitor rogocekib (CTX-712), CDK12 inhibitor CTX-439, GCN2 inhibitor |
| Launch date | 15 July 2026 (scheduled speaking date; the event will be held from 15 to 19 July 2026) |
| Applicable area | Oncology research and development, pharmaceuticals and biotechnology, and business partnering |
| Location | Fujisawa, Kanagawa Prefecture (head office) |
Items this document does not state (14)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To showcase the research and development pipeline and business strategy, while continuing efforts to create business partnering opportunities for the pipeline.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.